How Ecstasy and Psilocybin are Shaking up Psychiatry



Over the past decade, FDA has begun to approve limited controlled studies to explore the therapeutic potentials of psychedelic medicines. Two of the most promising and popular study subjects are MDMA & Psilocybin. As hopeful results begin to emerge through multiple phase II and phase III studies, the field of psychiatry is beginning to experience a long-due and promising renaissance in care.


Nature Research Journal recently published an in-depth report of how MDMA (ecstasy) and psilocybin are offering groundbreaking promise in the treatment of varying depressive and anxiety disorders, as well as the findings across various research trials.


"Psychedelic-assisted psychotherapy could provide needed options for debilitating mental-health disorders including PTSD, major depressive disorder, alcohol-use disorder, anorexia nervosa and more that kill thousands every year in the United States, and cost billions worldwide in lost productivity."





"Several trials show dramatic results: in a study published in November 2020, for example, 71% of people who took psilocybin for major depressive disorder showed a greater than 50% reduction in symptoms after four weeks, and half of the participants entered remission1. Some follow-up studies after therapy, although small, have shown lasting benefits."



Read The Original Article >>

Optimize Your Microdosing Practice!

 

Integrative Support & Personalized Protocols By Microdose Guru

DISCLAIMER

The perspectives and recommendations in this newsletter are not made by a medical professional and should not be considered medical advice. Readers are encouraged to consult their physician before taking any supplements or substances. 

 

While we believe that psychedelic medicines must be decriminalized, psychedelic substances are still considered  "Schedule I" substances in the US and continue to be subject to strong enforcement across nearly all states. The reader is responsible for checking their local rules and regulations and making informed decisions with all risk considerations. Microdose Guru does not endorse or accept liability for its readers' personal choices.